ARS Pharmaceuticals, Inc. (SPRY) — Operating Income
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$179.45M | -5720.6% |
| 2024 | -$3.08M | +95.4% |
| 2023 | -$67.52M | -90.1% |
| 2022 | -$35.52M | -82.6% |
| 2021 | -$19.45M | +40.9% |
| 2020 | -$32.92M | — |
| Fiscal Year | Operating Income | Change YoY |
|---|---|---|
| 2025 | -$179.45M | -5720.6% |
| 2024 | -$3.08M | +95.4% |
| 2023 | -$67.52M | -90.1% |
| 2022 | -$35.52M | -82.6% |
| 2021 | -$19.45M | +40.9% |
| 2020 | -$32.92M | — |